Related Experiment Videos
Long-acting somatostatin analogues in pancreatic islet cell carcinoma
1INSERM, U. 145, Hôpital Edouard-Herriot, Lyon, France.
Abstract:
In secreting islet cell carcinoma, the long-acting somatostatin analogue, Sandostatin, reduces symptoms of endocrine secretion both by inhibiting peptide secretion and by acting on the target organs. It could be used during the initial evaluation of patients with such tumors and thereafter when the tumor cannot be found or is metastatic. Its efficacy depends upon the tumor type and probably the presence of somatostatin receptors on the tumoral cells. It could decrease with time, especially in VIPomas. Side effects are few and usually mild. Hypoglycemia attacks in insulinoma could be worsened during treatment by the complete inhibition of hyperglycemic hormones. The inhibition of tumoral growth, based on animal models, appears infrequent in clinical practice.
Insights
Sandostatin, a somatostatin analogue, effectively manages symptoms in secreting islet cell carcinoma by inhibiting peptide secretion. Its efficacy varies by tumor type and receptor presence, with minimal side effects but potential risks in insulinomas.
Area of Science:
- Endocrinology
- Oncology
- Pharmacology
Background:
- Secreting islet cell carcinoma presents challenges in symptom management.
- Endocrine hypersecretion is a hallmark of these tumors.
Purpose of the Study:
- To evaluate the efficacy of Sandostatin (somatostatin analogue) in managing symptoms of secreting islet cell carcinoma.
- To assess the role of Sandostatin in tumor evaluation and metastatic disease.
Main Methods:
- Administration of Sandostatin to patients with secreting islet cell carcinoma.
- Monitoring of symptom reduction and endocrine secretion.
- Assessment of tumor response and side effects.
Main Results:
- Sandostatin reduces symptoms by inhibiting peptide secretion and affecting target organs.
- Efficacy is dependent on tumor type and somatostatin receptor expression.
- Tumor growth inhibition is infrequent in clinical practice, though side effects are generally mild.
Conclusions:
- Sandostatin is a valuable tool for symptom control in secreting islet cell carcinoma.
- Treatment requires consideration of tumor characteristics and potential adverse effects, particularly in insulinomas.